The Development and Commercialisation of Novel Antibiotic Compounds

新型抗生素化合物的开发和商业化

• 批准号: 100953
• 金额: $ 11.07万
• 依托单位: DEMURIS LIMITED
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2011
• 资助国家: 英国
• 起止时间: 2011 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=100953
• 关键词: Development; Commercialisation; Novel; Antibiotic; Compounds

Infectious diseases remain a leading cause of global deaths. New diseases and the continuous rise of multi-drug resistant bacteria suggest that there will be a continual need for novel antibacterial therapies with superior activity and better tolerance. However the number of antibiotic compounds in development is worryingly small.Demuris has screened a unique collection of bacterial isolates and has identified three potentially novel antibiotics. This project has developed these compounds from the early stages of discovery through to a point where the compounds can be evaluated for viability of commercialisation and pre-clinical development. The National Industrial Biotechnology Facility has provided the resources not currently available to Demuris and enabled the production of sufficient quantities of purified compounds for testing and development purposes.

传染病仍然是全球死亡的主要原因。新的疾病和多药耐药细菌的不断增加表明，将持续需要具有上级活性和更好耐受性的新型抗菌疗法。然而，开发中的抗生素化合物的数量少得令人担忧。Demuris筛选了一批独特的细菌分离物，并鉴定了三种潜在的新型抗生素。该项目从发现的早期阶段开发了这些化合物，直到可以评估这些化合物的商业化和临床前开发的可行性。国家工业生物技术设施提供了Demuris目前无法获得的资源，使其能够生产足够数量的纯化化合物，用于测试和开发目的。